BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV Trademark
Trademark Overview
On Tuesday, December 13, 2022, a trademark application was filed for BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV with the United States Patent and Trademark Office. The USPTO has given the BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV trademark a serial number of 97715586. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Monday, March 4, 2024. This trademark is owned by TG THERAPEUTICS, INC.. The BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV trademark is filed in the Pharmaceutical Products category with the following description:
pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
General Information
| Serial Number | 97715586 |
| Word Mark | BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV |
| Filing Date | Tuesday, December 13, 2022 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Monday, March 4, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, July 11, 2023 |
Trademark Statements
| Description of Mark | The mark consists of the text "BRIUMVI" above the text "UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV" with the "B" in "BRIUMVI" partially surrounded by a sphere edged by a circular line; the colors grey and white represent shaded and transparent areas and are not claimed as a feature of the mark. |
| Goods and Services | pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Translation of Words in Mark | The wording BRIUMVI has no meaning in a foreign language. |
| Disclaimer with Predetermined Text | "150 MG/6ML INJECTION FOR IV" |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 10, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | TG THERAPEUTICS, INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10014 |
| Party Name | TG THERAPEUTICS, INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10014 |
Trademark Events
| Event Date | Event Description |
| Tuesday, March 5, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 4, 2024 | SOU EXTENSION 1 GRANTED |
| Monday, March 4, 2024 | SOU EXTENSION 1 FILED |
| Monday, March 4, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, September 5, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 11, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 11, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, June 21, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, June 7, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, June 6, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, June 6, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, June 6, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, March 9, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, March 9, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, March 9, 2023 | NON-FINAL ACTION WRITTEN |
| Wednesday, March 8, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, January 11, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Tuesday, January 10, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, December 16, 2022 | NEW APPLICATION ENTERED |
